Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: Insights from saturn

Rishi Puri, Steven E. Nissen, Mingyuan Shao, Christie M. Ballantyne, Phillip J. Barter, M. John Chapman, Raimund Erbel, Peter Libby, Joel S. Raichlen, Kiyoko Uno, Yu Kataoka, Stephen J. Nicholls

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

RESULTS Compared with men (n =765), women (n =274) were older (p < 0.001) and more likely to have hypertension (p < 0.001), diabetes (p =0.002), and higher low-density lipoprotein cholesterol (LDL-C) (p =0.01), high-density lipoprotein cholesterol (p < 0.001), and C-reactive protein (CRP) (p =0.004) levels. At follow-up, women had higher high-density lipoprotein cholesterol (p < 0.001) and CRP (p < 0.001), but similar LDL-C (p =0.46) levels compared with men. Compared with men, women had lower baseline PAV (34.0 ± 8.0% vs. 37.2 ± 8.2%, p < 0.001) and TAV (122.4 ± 55 mm3 vs. 151.9 ± 63 mm3, p < 0.001), yet demonstrated greater PAV regression (-1.52 ± 0.18% vs. -1.07 ± 0.10%, p =0.03) and TAV regression (-8.27 ± 0.9 mm3 vs. -6.59 ± 0.50 mm3, p =0.11) following treatment. Greater PAV regression in women versus men occurred with rosuvastatin (p =0.004), those with diabetes (p =0.01), stable coronary disease (p =0.01), higher baseline LDL-C (p =0.02), and higher CRP (p =0.04) levels. On multivariable analysis, female sex was independently associated with PAV regression (p =0.01), and a sex-treatment interaction was found (p =0.036). For participants with on-treatment LDL-C levels <70 mg/dl, women achieved greater PAV regression (-1.81 ± 0.22% vs. -1.12 ± 0.13%, p =0.007) and TAV regression (-10.1 ± 1.1 mm3 vs. -7.16 ± 0.65 mm3, p =0.023) than men, whereas PAV and TAV regression did not differ by sex, with LDL-C levels $70 mg/dl.

CONCLUSIONS Women with coronary disease demonstrate greater coronary atheroma regression than men when empirically prescribed guideline-driven potent statin therapy. This benefit appears in the setting of lower on-treatment LDL-C levels. (CRESTOR Athero Imaging Head to Head IVUS Study [SATURN]; NCT000620542) (J Am Coll Cardiol Img 2014;7:1013-22.

OBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy. ±absp

BACKGROUND Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease.

METHODS SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ significantly in change from baseline of percent atheroma volume (PAV) or total atheroma volume (TAV) on intravascular ultrasound, nor in safety or clinical outcomes.

LanguageEnglish
Pages1013-1022
Number of pages10
JournalJACC: Cardiovascular Imaging
Volume7
Issue number10
DOIs
Publication statusPublished - 1 Oct 2014

Keywords

  • atherosclerosis
  • atorvastatin
  • IVUS
  • rosuvastatin
  • statins

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., ... Nicholls, S. J. (2014). Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: Insights from saturn. JACC: Cardiovascular Imaging, 7(10), 1013-1022. https://doi.org/10.1016/j.jcmg.2014.04.019
Puri, Rishi ; Nissen, Steven E. ; Shao, Mingyuan ; Ballantyne, Christie M. ; Barter, Phillip J. ; Chapman, M. John ; Erbel, Raimund ; Libby, Peter ; Raichlen, Joel S. ; Uno, Kiyoko ; Kataoka, Yu ; Nicholls, Stephen J. / Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy : Insights from saturn. In: JACC: Cardiovascular Imaging. 2014 ; Vol. 7, No. 10. pp. 1013-1022.
@article{19a762d06d25419884679cca7d49a9ec,
title = "Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: Insights from saturn",
abstract = "RESULTS Compared with men (n =765), women (n =274) were older (p < 0.001) and more likely to have hypertension (p < 0.001), diabetes (p =0.002), and higher low-density lipoprotein cholesterol (LDL-C) (p =0.01), high-density lipoprotein cholesterol (p < 0.001), and C-reactive protein (CRP) (p =0.004) levels. At follow-up, women had higher high-density lipoprotein cholesterol (p < 0.001) and CRP (p < 0.001), but similar LDL-C (p =0.46) levels compared with men. Compared with men, women had lower baseline PAV (34.0 ± 8.0{\%} vs. 37.2 ± 8.2{\%}, p < 0.001) and TAV (122.4 ± 55 mm3 vs. 151.9 ± 63 mm3, p < 0.001), yet demonstrated greater PAV regression (-1.52 ± 0.18{\%} vs. -1.07 ± 0.10{\%}, p =0.03) and TAV regression (-8.27 ± 0.9 mm3 vs. -6.59 ± 0.50 mm3, p =0.11) following treatment. Greater PAV regression in women versus men occurred with rosuvastatin (p =0.004), those with diabetes (p =0.01), stable coronary disease (p =0.01), higher baseline LDL-C (p =0.02), and higher CRP (p =0.04) levels. On multivariable analysis, female sex was independently associated with PAV regression (p =0.01), and a sex-treatment interaction was found (p =0.036). For participants with on-treatment LDL-C levels <70 mg/dl, women achieved greater PAV regression (-1.81 ± 0.22{\%} vs. -1.12 ± 0.13{\%}, p =0.007) and TAV regression (-10.1 ± 1.1 mm3 vs. -7.16 ± 0.65 mm3, p =0.023) than men, whereas PAV and TAV regression did not differ by sex, with LDL-C levels $70 mg/dl.CONCLUSIONS Women with coronary disease demonstrate greater coronary atheroma regression than men when empirically prescribed guideline-driven potent statin therapy. This benefit appears in the setting of lower on-treatment LDL-C levels. (CRESTOR Athero Imaging Head to Head IVUS Study [SATURN]; NCT000620542) (J Am Coll Cardiol Img 2014;7:1013-22.OBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy. ±abspBACKGROUND Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease.METHODS SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ significantly in change from baseline of percent atheroma volume (PAV) or total atheroma volume (TAV) on intravascular ultrasound, nor in safety or clinical outcomes.",
keywords = "atherosclerosis, atorvastatin, IVUS, rosuvastatin, statins",
author = "Rishi Puri and Nissen, {Steven E.} and Mingyuan Shao and Ballantyne, {Christie M.} and Barter, {Phillip J.} and Chapman, {M. John} and Raimund Erbel and Peter Libby and Raichlen, {Joel S.} and Kiyoko Uno and Yu Kataoka and Nicholls, {Stephen J.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.jcmg.2014.04.019",
language = "English",
volume = "7",
pages = "1013--1022",
journal = "JACC: Cardiovascular Imaging",
issn = "1936-878X",
publisher = "Elsevier Inc.",
number = "10",

}

Puri, R, Nissen, SE, Shao, M, Ballantyne, CM, Barter, PJ, Chapman, MJ, Erbel, R, Libby, P, Raichlen, JS, Uno, K, Kataoka, Y & Nicholls, SJ 2014, 'Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: Insights from saturn', JACC: Cardiovascular Imaging, vol. 7, no. 10, pp. 1013-1022. https://doi.org/10.1016/j.jcmg.2014.04.019

Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy : Insights from saturn. / Puri, Rishi; Nissen, Steven E.; Shao, Mingyuan; Ballantyne, Christie M.; Barter, Phillip J.; Chapman, M. John; Erbel, Raimund; Libby, Peter; Raichlen, Joel S.; Uno, Kiyoko; Kataoka, Yu; Nicholls, Stephen J.

In: JACC: Cardiovascular Imaging, Vol. 7, No. 10, 01.10.2014, p. 1013-1022.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy

T2 - JACC: Cardiovascular Imaging

AU - Puri, Rishi

AU - Nissen, Steven E.

AU - Shao, Mingyuan

AU - Ballantyne, Christie M.

AU - Barter, Phillip J.

AU - Chapman, M. John

AU - Erbel, Raimund

AU - Libby, Peter

AU - Raichlen, Joel S.

AU - Uno, Kiyoko

AU - Kataoka, Yu

AU - Nicholls, Stephen J.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - RESULTS Compared with men (n =765), women (n =274) were older (p < 0.001) and more likely to have hypertension (p < 0.001), diabetes (p =0.002), and higher low-density lipoprotein cholesterol (LDL-C) (p =0.01), high-density lipoprotein cholesterol (p < 0.001), and C-reactive protein (CRP) (p =0.004) levels. At follow-up, women had higher high-density lipoprotein cholesterol (p < 0.001) and CRP (p < 0.001), but similar LDL-C (p =0.46) levels compared with men. Compared with men, women had lower baseline PAV (34.0 ± 8.0% vs. 37.2 ± 8.2%, p < 0.001) and TAV (122.4 ± 55 mm3 vs. 151.9 ± 63 mm3, p < 0.001), yet demonstrated greater PAV regression (-1.52 ± 0.18% vs. -1.07 ± 0.10%, p =0.03) and TAV regression (-8.27 ± 0.9 mm3 vs. -6.59 ± 0.50 mm3, p =0.11) following treatment. Greater PAV regression in women versus men occurred with rosuvastatin (p =0.004), those with diabetes (p =0.01), stable coronary disease (p =0.01), higher baseline LDL-C (p =0.02), and higher CRP (p =0.04) levels. On multivariable analysis, female sex was independently associated with PAV regression (p =0.01), and a sex-treatment interaction was found (p =0.036). For participants with on-treatment LDL-C levels <70 mg/dl, women achieved greater PAV regression (-1.81 ± 0.22% vs. -1.12 ± 0.13%, p =0.007) and TAV regression (-10.1 ± 1.1 mm3 vs. -7.16 ± 0.65 mm3, p =0.023) than men, whereas PAV and TAV regression did not differ by sex, with LDL-C levels $70 mg/dl.CONCLUSIONS Women with coronary disease demonstrate greater coronary atheroma regression than men when empirically prescribed guideline-driven potent statin therapy. This benefit appears in the setting of lower on-treatment LDL-C levels. (CRESTOR Athero Imaging Head to Head IVUS Study [SATURN]; NCT000620542) (J Am Coll Cardiol Img 2014;7:1013-22.OBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy. ±abspBACKGROUND Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease.METHODS SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ significantly in change from baseline of percent atheroma volume (PAV) or total atheroma volume (TAV) on intravascular ultrasound, nor in safety or clinical outcomes.

AB - RESULTS Compared with men (n =765), women (n =274) were older (p < 0.001) and more likely to have hypertension (p < 0.001), diabetes (p =0.002), and higher low-density lipoprotein cholesterol (LDL-C) (p =0.01), high-density lipoprotein cholesterol (p < 0.001), and C-reactive protein (CRP) (p =0.004) levels. At follow-up, women had higher high-density lipoprotein cholesterol (p < 0.001) and CRP (p < 0.001), but similar LDL-C (p =0.46) levels compared with men. Compared with men, women had lower baseline PAV (34.0 ± 8.0% vs. 37.2 ± 8.2%, p < 0.001) and TAV (122.4 ± 55 mm3 vs. 151.9 ± 63 mm3, p < 0.001), yet demonstrated greater PAV regression (-1.52 ± 0.18% vs. -1.07 ± 0.10%, p =0.03) and TAV regression (-8.27 ± 0.9 mm3 vs. -6.59 ± 0.50 mm3, p =0.11) following treatment. Greater PAV regression in women versus men occurred with rosuvastatin (p =0.004), those with diabetes (p =0.01), stable coronary disease (p =0.01), higher baseline LDL-C (p =0.02), and higher CRP (p =0.04) levels. On multivariable analysis, female sex was independently associated with PAV regression (p =0.01), and a sex-treatment interaction was found (p =0.036). For participants with on-treatment LDL-C levels <70 mg/dl, women achieved greater PAV regression (-1.81 ± 0.22% vs. -1.12 ± 0.13%, p =0.007) and TAV regression (-10.1 ± 1.1 mm3 vs. -7.16 ± 0.65 mm3, p =0.023) than men, whereas PAV and TAV regression did not differ by sex, with LDL-C levels $70 mg/dl.CONCLUSIONS Women with coronary disease demonstrate greater coronary atheroma regression than men when empirically prescribed guideline-driven potent statin therapy. This benefit appears in the setting of lower on-treatment LDL-C levels. (CRESTOR Athero Imaging Head to Head IVUS Study [SATURN]; NCT000620542) (J Am Coll Cardiol Img 2014;7:1013-22.OBJECTIVES The study sought to explore sex-related differences in coronary atheroma regression following high-intensity statin therapy. ±abspBACKGROUND Guidelines now recommend high-intensity statins in all individuals with atherosclerotic cardiovascular disease.METHODS SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin) employed serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. The treatment groups did not differ significantly in change from baseline of percent atheroma volume (PAV) or total atheroma volume (TAV) on intravascular ultrasound, nor in safety or clinical outcomes.

KW - atherosclerosis

KW - atorvastatin

KW - IVUS

KW - rosuvastatin

KW - statins

UR - http://www.scopus.com/inward/record.url?scp=84908038000&partnerID=8YFLogxK

U2 - 10.1016/j.jcmg.2014.04.019

DO - 10.1016/j.jcmg.2014.04.019

M3 - Article

VL - 7

SP - 1013

EP - 1022

JO - JACC: Cardiovascular Imaging

JF - JACC: Cardiovascular Imaging

SN - 1936-878X

IS - 10

ER -